Singapore grants interim approval for Moderna's bivalent COVID-19 booster vaccine

India Pharma Outlook Team | Thursday, 15 September 2022

 India Pharma Outlook Team

Singapore granted interim authorisation for a bivalent COVID-19 booster vaccine made by Moderna, the government said in a statement.

The vaccine has been authorised for use as a booster shot in individuals aged 18 years and above who have received the primary series of COVID-19 vaccinations, the city-state's Health Sciences Authority said. Moderna's bivalent vaccine contains mRNA designed to target two different coronavirus variants - the original variant from 2020 and the Omicron variant that was circulating widely last winter.

© 2025 India Pharma Outlook. All Rights Reserved.